Priority Review in the USA for new Enhertu indication

28 October 2020
daiichi-sankyo-logo-big

A further boost for antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has come in the form of Priority Review designation and acceptance from the US regulator.

The drug’s developers, AstraZeneca (LSE: AZN) and Daiichi Sankyo (TYO: 4568), were granted the speedy review for a bid to widen the label to include people with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.

Enhertu is the only HER2-directed medicine to demonstrate significant improvement in overall survival (OS), compared to chemo, in this later-line treatment setting.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology